Flaws In China’s Drug Regulatory Process Revealed In Herbal Injection Recall
This article was originally published in PharmAsia News
Executive Summary
China's Ministry of Health and State FDA have issued an urgent notice to recall two batches of Ciwujia injection produced by Wandashan Pharmaceutical after adverse effects resulting in three deaths were reported. Although the investigation is still ongoing, experts think that the deaths were mainly caused by impurities in the herbal injection. For food and drug supervision, China currently only tests active components. Control is lax on impurities testing; furthermore, the complex nature of traditional Chinese medicine components means some impurities cannot be detected. Industry analysts observe that despite the country's repeated adverse drug incidents, the negative impact on TCM injections will probably be short term as the products still have big market potential due to their low cost. (Click here for more - Chinese Language)
You may also be interested in...
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.
Roche Gets Adjuvant ALK+ Lung Cancer To Itself With Alecensa Approval
The US FDA cleared Roche’s supplemental approval request for ALK inhibitor Alecensa in ALK-positive non-small cell lung cancer following tumor resection.